| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42e94091a4fc81b8d0237117707cc7ee |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 |
| filingDate |
2007-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fafdc197e7ea8f5f02dd266b389772d2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b8e2c0f4ece34f59d4308c61aa3bdad3 |
| publicationDate |
2010-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2010081662-A1 |
| titleOfInvention |
Pyrrolotriazine kinase inhibitors |
| abstract |
The invention provides compounds of formula I n n n n n n n n n n and pharmaceutically acceptable salts thereof. n The formula I compounds inhibit tyrosine kinase activity of Trk receptors such as TrkA, TrkB, TrkC or Flt-3 thereby making them useful as anticancer agents. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8592579-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011124623-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011194572-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8263765-B2 |
| priorityDate |
2006-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |